This link will take you to a page that’s not on LinkedIn

Because this is an external link, we’re unable to verify it for safety.

https://normunity.com/normunity-announces-first-patient-dosed-in-phase-1-clinical-study-of-nrm-823-a-t-cell-engager-against-a-novel-tumor-specific-target-in-patients-with-solid-tumors/